A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt. Among all vaccinated patients, including 70 treated prior to progression (pr…

Prion protein may play key role in progression of glioblastoma

Glioblastoma (GBM), one of the most aggressive types of brain cancer, is one of the greatest challenges for medicine, both because it is difficult to treat and because of its high mortality rate. In Brazil, although no exact figures are available, it is estimated that between 10,000 and 12,000 new cases are diagnosed every year.